SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Technology Stocks : CDMA, Globalstar versus Iridium, Inmarsat, etc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Maurice Winn who wrote (344)2/4/1998 3:54:00 AM
From: Maurice Winn  Read Replies (1) of 381
 
"Lastly, I agree that in a 2cm node the use of Radiation (XRT) is probably not indicated in most cases." Well, that isn't what they think for Tarken. They say radiation is necessary [with some dissenting opinion] to back up 3xCHOP. Based on a recent study called "SWOG" which was reported in abstract by the American Society of Clinical Oncologists [ASCO] which said that 3 doses of CHOP plus involved field radiation is as good as 6 doses of CHOP alone.

So we are off to San Diego on Monday to see whether Rituxan will be a useful adjunct therapy for Tarken.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News